TNFAIP3 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon7.
Images
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon7.
Alternative names
AISBL, MGC104522, MGC138687, MGC138688, OTU domain-containing protein 7C, OTUD7C, Putative DNA-binding protein A20, TNAP3_HUMAN, TNF alpha-induced protein 3, TNFA1P2, TNFAIP3 (A20), Tumor necrosis factor alpha-induced protein 3, Tumor necrosis factor induced protein 3, Tumor necrosis factor inducible protein A20, Zinc finger protein A20
What's included?
Recommended products
TNFAIP3 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon7.
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon7.
- Disease
- Adenocarcinoma
- Concentration
Properties
- Gene name
- TNFAIP3
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing, Western blot
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
3 product images
Western blot - Human TNFAIP3 knockout HeLa cell lysate (ab257112)
Lane 1: Wild-type HeLa cell lysate (20 μg)Lane 2: TNFAIP3 knockout HeLa cell lysate (20 μg)
Lane 3: Jurkat cell treated with 5ng/ml PMA for 48 hours and then treated with 2μg/ml PHA for 48 hours, whole cell lysate (20 μg)
Lane 4: Untreated Jurkat cell lysate (20 μg)
Lanes 1-4: Merged signal (red and green). Green - Anti-TNFAIP3 antibody [EPR2663] ab92324 observed at 80 kDa. Red - loading control, Anti-GAPDH antibody [6C5] - Loading Control ab8245 observed at 37 kDa.
Anti-TNFAIP3 antibody [EPR2663] ab92324 Anti-TNFAIP3 antibody [EPR2663] was shown to specifically react with TNFAIP3 in wild-type HeLa cells. Loss of signal was observed when knockout cell line Human TNFAIP3 knockout HeLa cell line ab265983 (knockout cell lysate ab257112) was used. Wild-type and TNFAIP3 knockout samples were subjected to SDS-PAGE. Anti-TNFAIP3 antibody [EPR2663] ab92324 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 10000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-TNFAIP3 antibody [EPR2663] (Anti-TNFAIP3 antibody [EPR2663] ab92324) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: TNFAIP3 knockout HeLa cell lysate at 20 µg
Lane 3: Jurkat cell treated with 5ng/ml PMA for 48 hours and then treated with 2µg/ml PHA for 48 hours, whole cell lysate at 20 µg
Lane 4: Untreated Jurkat cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 89 kDa
Observed band size: 80 kDa
Western blot - Human TNFAIP3 knockout HeLa cell lysate (ab257112)
Lane 1: Wild-type HeLa cell lysate (20 μg)Lane 2: TNFAIP3 knockout HeLa cell lysate (20 μg)
Lane 3: Jurkat cell treated with 5ng/ml PMA for 48 hours and then treated with 2μg/ml PHA for 48 hours, whole cell lysate (20 μg)
Lane 4: Untreated Jurkat cell lysate (20 μg)
Lanes 1-4: Merged signal (red and green). Green - Anti-TNFAIP3 antibody [59A426] ab13597 observed at 80 kDa. Red - loading control, Anti-GAPDH antibody [EPR16891] - Loading Control ab181602 observed at 37 kDa.
Anti-TNFAIP3 antibody [59A426] ab13597 Anti-TNFAIP3 antibody [59A426] was shown to specifically react with TNFAIP3 in wild-type HeLa cells. Loss of signal was observed when knockout cell line Human TNFAIP3 knockout HeLa cell line ab265983 (knockout cell lysate ab257112) was used. Wild-type and TNFAIP3 knockout samples were subjected to SDS-PAGE. Anti-TNFAIP3 antibody [59A426] ab13597 and Anti-GAPDH antibody [EPR16891] - Loading Control (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) were incubated overnight at 4°C at 1 in 500 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed ab216777) secondary antibodies at 1 in 10000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-TNFAIP3 antibody [59A426] (Anti-TNFAIP3 antibody [59A426] ab13597) at 1/500 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: TNFAIP3 knockout HeLa cell lysate at 20 µg
Lane 3: Jurkat cell treated with 5ng/ml PMA for 48 hours and then treated with 2µg/ml PHA for 48 hours, whole cell lysate at 20 µg
Lane 4: Untreated Jurkat cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 89 kDa
Observed band size: 80 kDa
Sanger Sequencing - Human TNFAIP3 knockout HeLa cell lysate (ab257112)
Homozygous: 1 bp insertion in exon7
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com